Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin
Circulation · 24.02.2026 · 153 (8) · 567-575
DOI: 10.1161/circulationaha.125.075275 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Circulation, erschienen am 24.02.2026. Verfasst von Samer Al Said und 12 weiteren Autor:innen. Beteiligte Einrichtung: Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Anticoagulants, Embolism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Systemic embolic events (SEEs) are a serious but underrecognized complication of atrial fibrillation. Although non–vitamin K antagonist oral anticoagulants prevent ischemic stroke (IS), their efficacy in SEE and the clinical characteristics of patients who experience SEE remain poorly understood. METHODS: We analyzed individual patient data from 4 pivotal randomized trials enrolling patients between 2005 and 2010 comparing non–vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation. We characterized the incidence, clinical features, management, and outcomes of clinically overt SEE and compared results in these patients with patients who had an IS. RESULTS: Among 71 683 patients, 188 experienced SEE (26 with concurrent IS), yielding an annualized event rate of 0.13% per patient-year, compared with 1.25% per patient-year for IS (n=1797). Among 171 patients with SEE as their first event, median age was 75 years (interquartile range, 68–80), 49.7% were female, and mean±SD CHA 2 DS 2 -VASc score was 4. 7 ±1.5. Compared with IS, patients with SEE had higher rates of peripheral arterial disease (PAD, 16.5% versus 5.4%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (S.A.S., E.B., M.G.P., G.E.M.M., C.T.R., E.M.A., R.…
- Division of Cardiovascular Medicine, Maine Medical Center, Portland (B.J.G.).
- Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston (A.P.C.).
- Department of Medicine, McMaster University, Hamilton, Canada (J.W.E.).
- Duke Clinical Research Institute, Duke University, Durham, NC (C.B.G., M.R.P).
- Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden (L.W.).
ORCID-Profile: Samer Al Said, Michael G Palazzolo, Giorgio E M Melloni, Bram J Geller, Christian T Ruff, Anthony P Carnicelli, John W Eikelboom, Christopher B Granger, Manesh R Patel, Lars Wallentin, Robert P Giugliano
Zitieren
APA
Al Said, S., Braunwald, E., Palazzolo, M. G., Melloni, G. E. M., Geller, B. J., Ruff, C. T., Antman, E. M., Carnicelli, A. P., Eikelboom, J. W., Granger, C. B., Patel, M. R., Wallentin, L., & Giugliano, R. P. (2026). Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. Circulation, 153(8), 567-575. https://doi.org/10.1161/circulationaha.125.075275
Vancouver
Al Said S, Braunwald E, Palazzolo MG, Melloni GEM, Geller BJ, Ruff CT, et al. Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. Circulation. 2026;153(8):567-575. doi:10.1161/circulationaha.125.075275
BibTeX
@article{AlSaid2026,
author = {Al Said, Samer and Braunwald, Eugene and Palazzolo, Michael G and Melloni, Giorgio E M and Geller, Bram J and Ruff, Christian T and Antman, Elliott M and Carnicelli, Anthony P and Eikelboom, John W and Granger, Christopher B and Patel, Manesh R and Wallentin, Lars and Giugliano, Robert P},
title = {Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin},
journal = {Circulation},
year = {2026},
volume = {153},
number = {8},
pages = {567--575},
doi = {10.1161/circulationaha.125.075275}
}
EUVIMED